The Coagulation Factors Fibrinogen, Thrombin, and Factor XII in Inflammatory Disorders—A Systematic Review

Göbel, Kerstin; Eichler, Susann; Wiendl, Heinz; Chavakis, Triantafyllos; Kleinschnitz, Christoph; Meuth, Sven G.

doi:10.3389/fimmu.2018.01731

Cited by 160 publications

(140 citation statements)

References 100 publications

Supporting

Mentioning

127

Contrasting

Unclassified

Order By: Relevance

“…As traditional markers of brinolysis, FDP and D-dimer have been analyzed for monitoring venous thromboembolism and preoperative coagulation control. Recently there are several studies reporting that FDP and D-dimer levels were elevated in the setting of systemic in ammation and infection [25,31,32]. A previous study reported that that the rise and fall of serum D-dimer is more rapid than serum CRP and ESR in patients with periprosthetic joint infection and the test of serum D-dimer might be applied effectively in diagnosing early postoperative infection [33].…”

Section: Discussionmentioning

confidence: 99%

Plasma Fibrinogen, D-dimer, and Fibrin Degradation Product as Biomarkers of Rheumatoid Arthritis

et al. 2020

Preprint

View full text Add to dashboard Cite

Objective: This study aimed to assess the role of coagulation-related indicators such as plasma ﬁbrinogen (FIB), D-dimer, and fibrin degradation product (FDP) in rheumatoid arthritis (RA) and their association with disease activity.Methods: Data from 105 RA patients and 102 age- and gender- matched healthy controls were collected in the retrospective study. Disease activity score in 28 joints based on C-reactive protein (DAS28-CRP) was used to divide the RA patients into inactive group (DAS28-CRP ≤ 2.7) and active group (DAS28-CRP > 2.7). The association between plasma FIB, D-dimer, and FDP and DAS28-CRP was evaluated by spearman correlation. Receiver operating characteristic (ROC) curve was applied to determine the area under curve (AUC) value. The prognostic value of plasma FIB, D-dimer, and FDP in the RA disease activity was tested by logistical regression analysis.Results: RA patients showed higher FAR levels of plasma FIB, D-dimer, and FDP than the controls (P < 0.01). Plasma FIB, D-dimer, and FDP were also increased in active group of RA patients than those in inactive group (P < 0.001). Spearman analysis showed that plasma FIB, D-dimer, and FDP were positively related with DAS28-CRP (P < 0.001) in RA patients. ROC curve analyses revealed that the AUC of D-dimer was higher than ESR and RF, and that of FDP was higher than RF in RA patients. In addition, the optimal cut-oﬀ value of plasma FIB, D-dimer, and FDP for RA diagnosis was 286 mg/dL, 470 μg/L, and 1.45 mg/L, respectively. Logistical regression analyses showed that D-dimer (odds ratio = 2.862, 95% conﬁdence interval: 1.851-4.426, P < 0.001) was a predictor for RA disease activity.Conclusions: FIB, D-dimer, and FDP were increased in RA patients and positively correlated with the disease activity of RA. D-dimer may act as a novel inﬂammatory parameter for predicting disease activity in RA patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Plasma Fibrinogen, D-dimer, and Fibrin Degradation Product as Biomarkers of Rheumatoid Arthritis

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…DEP, differentially expressed protein; HC, healthy control; AS, ankylosing spondylitis; ADA, adalimumab; Pre-ADA, pre-treated with ADA; Post-ADA, post-treated with ADA. (Brouwer et al, 2004;Gobel et al, 2018), were also AS-related. Recently, a large population-based cohort study disclosed AS was associated with a higher risk of venous thromboembolism (VTE) compared with people without AS (Avina-Zubieta et al, 2019).…”

Section: Discussionmentioning

confidence: 96%

Circulating Retinol-Binding Protein 4 as a Possible Biomarker of Treatment Response for Ankylosing Spondylitis: An Array-Based Comparative Study

Chen

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Objective: To explore proteins associated with ankylosing spondylitis (AS) and to investigate potential proteins that may predict treatment response of adalimumab (ADA) in AS patients. Methods: In the discovery cohort, 39 AS patients and 20 healthy controls (HCs) were included, and 16 AS patients received ADA treatment for 24 weeks after included. In the validation cohort, 43 AS patients and 39 HCs were enrolled, and all 43 patients received ADA treatment after enrollment. Blood samples and clinical information were collected from two cohorts at baseline from all participants and week 24 from patients received ADA treatment. A human antibody array containing 1,000 proteins was used in the discovery phase, and Elisa kits were used for protein validation. Results: Compared with HCs, we identified 53 differentially expressed proteins (DEPs) in AS patients. Bioinformatics analysis revealed they were mostly enriched in coagulation function-related pathways, acute response signaling, and LXR/RXR activation. Bone metabolism pathways were also associated. Comparison between samples of pre-and post-ADA treatment revealed 42 DEPs. They were mostly associated with bone metabolism and inflammation response pathways. Significant enrichment was also found in LXR/RXR activation but not the coagulation functionrelated pathways. Upstream regulator analysis suggested that most regulators also significantly functioned under usage of ADA. Precisely, seven proteins were abnormally expressed in AS and restored after ADA treatment. Retinol-binding protein 4 (RBP4), one of the seven proteins, was validated that its baseline levels were inversely correlated with improvements in Ankylosing Spondylitis Disease Activity Score-C-reactive protein (ASDAS-CRP). Likewise, percentage changes in RBP4 levels were inversely correlated with changes in ASDAS-CRP score. Conclusion: A dysregulated serum protein profile existed in AS. ADA exerted a considerable but not entire alteration toward the dysregulation. RBP4 could be a biomarker for predicting and monitoring ADA treatment response.

show abstract

“…The normal plasma concentration of fibrinogen is between 2 and 4 g/l; however, this concentration can rapidly increase under pathological conditions such as injury, infection, or inflammation [27]. Viral infections may induce severe complications such as acute respiratory distress syndrome and multiorgan failure which are often accompanied by hypercoagulation and DIC [28,29].…”

Section: Discussionmentioning

confidence: 99%

Elevated fibrinogen and fibrin degradation product are associated with poor outcome in COVID-19 patients: A meta-analysis

Nugroho

Wardhana

Mulia

et al. 2021

View full text Add to dashboard Cite

INTRODUCTION: COVID-19 is a systemic infection with a significant impact on coagulation which manifests in thromboembolism. There is an unknown relationship of which coagulation profile parameter at presentation has an association with poor outcome in COVID-19. OBJECTIVE: This meta-analysis aimed to determine the relationship between fibrinogen and FDP with poor outcome in COVID-19 patients. METHODS: A systematic search of all observational studies or trials involving adult patients with COVID-19 that had any data fibrinogen or FDP on admission was carried out using the PubMed, Science Direct, Scopus, ProQuest, and MedRxiv databases. We assessed the methodological quality assessment using the NIH Quality Assessment Tool. We performed random-effects inverse-variance weighting analysis using mean difference (MD). RESULTS: A total of 17 studies (1,654 patients) were included in this meta-analysis. It revealed a higher mean of fibrinogen levels on admission in patients with severe case compared to those with non-severe case (MD = 0.69, [95% CI: 0.44 to 0.94], p < 0.05; I2 = 72%, p < 0.05). Non-survivor group had a pooled higher mean difference of fibrinogen values on admission (MD = 0.48 [95% CI: 0.13 to 0.83], p < 0.05; I2 = 38%, p = 0.18). Higher FDP on admission was found in poor outcome (composite of severity, critically ill, and mortality) compared to good outcome (4 studies, MD = 4.84 [95% CI: 0.75 to 8.93], p < 0.05; I2 = 86%, p < 0.05). CONCLUSION: Elevated fibrinogen and FDP level on admission were associated with an increase risk of poor outcome in COVID-19 patients.

show abstract

The Coagulation Factors Fibrinogen, Thrombin, and Factor XII in Inflammatory Disorders—A Systematic Review

Cited by 160 publications

References 100 publications

Plasma Fibrinogen, D-dimer, and Fibrin Degradation Product as Biomarkers of Rheumatoid Arthritis

Plasma Fibrinogen, D-dimer, and Fibrin Degradation Product as Biomarkers of Rheumatoid Arthritis

Circulating Retinol-Binding Protein 4 as a Possible Biomarker of Treatment Response for Ankylosing Spondylitis: An Array-Based Comparative Study

Elevated fibrinogen and fibrin degradation product are associated with poor outcome in COVID-19 patients: A meta-analysis

Contact Info

Product

Resources

About